Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10838)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2019 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yao LT, Wang MZ, Wang MS, Yu XT, Guo JY, Sun T, Li XY, Xu YY. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World J Clin Cases 2019; 7(15): 1937-1953 [PMID: 31423426 DOI: 10.12998/wjcc.v7.i15.1937] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v7/i15/1937.htm |
| Number | Citing Articles |
| 1 |
Tingting Wei, Xia Li, Wanmin Qiang, Yan Zhang, Hailing Ren, Qiupeng Zhang, Xue Jin. Menopausal symptoms in breast cancer patients receiving adjuvant endocrine therapy and their relationships with health-promoting behaviors and social support. Menopause 2023; 30(3): 289 doi: 10.1097/GME.0000000000002130
|
| 2 |
Shurui Wang, Difei Huang, Xiaofeng Liu, Qiang Tang, Chenxi Xi, Yixin Ma, Huan Liu, Xing Chen, Aomei Shen, Maojun Di, Wanmin Qiang, Xian Du. Development and validation of a prediction model for frailty in breast cancer patients with extended survival. Supportive Care in Cancer 2024; 32(6) doi: 10.1007/s00520-024-08501-7
|
| 3 |
Huayao Li, Chundi Gao, Qing Liang, Cun Liu, Lijuan Liu, Jing Zhuang, Jing Yang, Chao Zhou, Fubin Feng, Changgang Sun. Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms. Frontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.592109
|
| 4 |
Ryeo-Eun Go, Cho-Won Kim, Sung-Moo Lee, Hong Kyu Lee, Kyung-Chul Choi. Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models. Food and Chemical Toxicology 2021; 149: 112000 doi: 10.1016/j.fct.2021.112000
|
| 5 |
Yi Li, Kexin Wang, Yupeng Chen, Jieqi Cai, Xuemei Qin, Aiping Lu, Daogang Guan, Genggeng Qin, Weiguo Chen. A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.723147
|
| 6 |
Nandini Dey, Jennifer Aske, Pradip De. Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR. Cancers 2021; 13(3): 458 doi: 10.3390/cancers13030458
|